Emmanuel Berl

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Retrieved on: 
Monday, January 9, 2023

RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.

Key Points: 
  • RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.
  • In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events.
  • The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo.
  • While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort.

AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

Retrieved on: 
Wednesday, January 19, 2022

AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome.

Key Points: 
  • AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome.
  • MCAS is a disease caused by inappropriate activation of mast cells, which can lead to mast cell mediator release symptoms with a severity ranging from mild to life-threatening.
  • Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.
  • AB Science disclaims any obligationor undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq.

Standard Lithium Appoints Dr. Volker Berl to Board of Directors

Retrieved on: 
Tuesday, July 20, 2021

VANCOUVER, British Columbia, July 20, 2021 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (Standard Lithium or the Company) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project development company, announces that effective immediately Dr. Volker Berl has been appointed as an independent director of the Company.

Key Points: 
  • VANCOUVER, British Columbia, July 20, 2021 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (Standard Lithium or the Company) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project development company, announces that effective immediately Dr. Volker Berl has been appointed as an independent director of the Company.
  • I am pleased to welcome Dr. Berl to the board at this significant juncture in the Companys evolution, said Robert Cross, Chair of Standard Lithiums board of directors.
  • I am excited to expand my involvement with Standard Lithium on the heels of the recent NYSE American listing and technological achievements, Dr. Berl stated.
  • I look forward to representing shareholders and working closely with the board and team as they continue to execute on their strategic developments plans.